Todos Medical

Todos Medical

Todos Medical is a Rehovot-based medical diagnostics developer of blood tests for cancer detection.

No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.

No article has been written about this topic yet.
Be the first one to add some text.

Loading AI-assisted edit mode...

Timeline

November 18, 2020
Todos Medical announces positive clinical proof of concept data from its lab-based rapid SARS-CoV-2.

November 17, 2020
Todos Medical announces clinical validation and National CLIA Certification for MOTO+PARA Mobile High Complexity Labs.

February 2016
Todos Medical raises a $59,200 grant from EASME.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Todos Medical, Grant, February 2016
59,200
February 2016
1 Result
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Rami Zigdon

Founder

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
FinancialBuzz.com
November 25, 2020
www.prnewswire.com:443
/PRNewswire/ -- As of earlier this week, the U.S. has reported more than 12.4 million cases and over 257,600 deaths, according to Johns Hopkins University data....
BioSpace
November 18, 2020
BioSpace
Todos Medical (OTCQB: TOMDF) , an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for early detection of cancer and Alzheimer's disease, today announced positive clinical proof of concept data from its lab-based rapid SARS-CoV-2 3CL protease diagnostic assay in collaboration with its COVID Antigen Te
BioSpace
November 17, 2020
BioSpace
Todos Medical (OTCQB: TOMDF) , an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer's disease, today announced the completion of clinical validation and CLIA certification for MOTO+PARA's mobile lab. The Company's mobile CLIA lab partner, Integrated Hea
FinancialBuzz.com
November 17, 2020
www.prnewswire.com:443
/PRNewswire/ -- Researchers seem to be getting closer and closer to a vaccine to properly fight the current pandemic. Yesterday, Moderna, Inc., a biotechnology...
FinancialBuzz.com
November 16, 2020
www.prnewswire.com:443
/PRNewswire/ -- New restrictions are being implemented in several states across the country as the number of those infected with COVID-19 is once again on the...
BioSpace
May 26, 2020
BioSpace
Todos gains distribution rights to LifeCan Ventilator in Brazil, Mexico & Latin America Ventilator access will help prospective government and NGO procurers of COVID-related medical products reduce need for additional suppliers to address critical health needs L1 distribution network will provide untapped market access for Todos' tests REHOVOT, Israel, SINGAPORE and NEW YORK, NY, May 26, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (OTCQB: TOMDF) , an in vi
BioSpace Editorial Staff
May 26, 2020
BioSpace
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 26, 2020.
BioSpace
May 11, 2020
BioSpace
Exclusive Distribution agreement covers North America, Latin America, SE Asia, Europe · Validation of Gnomegen qPCR kits now complete at CLIA/CAP-certified lab partner · Focus now on commercialization of combination PCR/antibody testing paradigm REHOVOT, Israel, SINGAPORE and NEW YORK, NY, May 11, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (OTCQB: TOMDF) , a commercial in vitro diagnostics company focused on the development of blood tests fo

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.